外陰陰道念珠菌病治療市場－全球產業規模、佔有率、趨勢、機會和預測，按藥物類別、給藥途徑、配銷通路、地區和競爭細分，2020-2030 年

2024 年全球外陰陰道念珠菌病治療市場價值為 9.8723 億美元，預計到 2030 年將達到 12.8716 億美元，預測期內的複合年成長率為 4.52%。全球外陰陰道念珠菌病治療市場正在經歷顯著成長，這得益於新型抗真菌藥物的不斷發展和全球醫療保健支出的不斷成長。此外，對低成本最佳治療方法的需求不斷成長，以及老齡人口的成長，顯著增加了全球不同地區對外陰陰道念珠菌病治療的需求。此外，全球癌症、心血管疾病、神經系統疾病和糖尿病等慢性疾病的盛行率不斷上升，預計將進一步增加對外陰陰道念珠菌病治療的需求，從而推動市場成長。此外，人們越來越意識到保持衛生以及使用低成本新療法的好處，預計也將在預測期內為外陰陰道念珠菌病治療市場提供支持。

此外，由於酵母菌感染，氟康唑等廣譜抗生素的使用量不斷增加，預計將進一步增加對外陰陰道念珠菌病治療的需求，從而支持市場成長。在美國，念珠菌病是繼細菌性陰道感染之後第二常見的陰道感染類型。據估計，每年有140萬人次因念珠菌病就診。

關鍵市場促進因素

外陰陰道念珠菌病及復發性感染盛行率上升

主要市場挑戰

抗真菌抗藥性和有限的治療效果

主要市場趨勢

轉向新型和非唑類抗真菌療法

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：臨床試驗分析

第6章：全球外陰陰道念珠菌病治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依藥物類別（克黴唑、制黴菌素、氟康唑、酮康唑、特比萘芬、特康唑等）
  • 依給藥途徑（口服、靜脈注射、外用）
  • 按配銷通路（醫院藥房、零售藥房、網路藥房）
  • 按地區
  • 按公司分類（2024）
• 市場地圖
  • 按藥物類別
  • 依給藥途徑
  • 按配銷通路
  • 按地區

第7章：北美外陰陰道念珠菌病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第8章：歐洲外陰陰道念珠菌病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第9章：亞太地區外陰陰道念珠菌病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第10章：南美洲外陰陰道念珠菌病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 11 章：中東和非洲外陰陰道念珠菌病治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 12 章：市場動態

• 驅動程式
• 挑戰

第13章：市場趨勢與發展

• 最新動態
• 併購
• 產品發布

第 14 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品/服務的威脅

第 15 章：SWOT 分析：全球外陰陰道念珠菌病治療市場

第 16 章：競爭格局

• Astellas Pharma Inc.
• Mycovia Pharmaceuticals, Inc.
• Basilea Pharmaceutica Ltd.
• Scynexis, Inc.
• Grupo Ferrer Internacional, SA
• Pfizer, Inc.
• Pacgen Life Science Corporation
• NovaDigm Therapeutics, Inc.
• Cidara Therapeutics, Inc.
• Amplyx Pharmaceuticals Inc.

第 17 章：策略建議

第18章調查會社について,免責事項

Global Vulvovaginal Candidiasis Treatment Market was valued at USD 987.23 Million in 2024 and is expected to reach USD 1287.16 Million by 2030 with a CAGR of 4.52% during the forecast period. The global market for Vulvovaginal Candidiasis Treatment is experiencing significant growth, driven by the growing development of new antifungal drugs and growing healthcare expenditure across the globe. Additionally, growing demand for the best treatment with low cost, along with growing geriatric population have significantly increased the demand for vulvovaginal candidiasis treatment across different parts of the globe. Additionally, increasing prevalence of chronic diseases like cancer, cardiovascular diseases, neurological diseases, and diabetes across the globe is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby fuelling the market growth. Besides, growing awareness on maintaining hygiene and benefits of using new treatments with lower cost is further expected to support the vulvovaginal candidiasis treatment market during the forecast period.

Furthermore, increasing usage of broad-spectrum antibiotic such as Fluconazole because of yeast infection is further expected to increase the demand for vulvovaginal candidiasis treatment, thereby supporting the market growth. It is the second most common type of vaginal infection after bacterial vaginal infections, in the United States. An estimated 1.4 million outpatient visits for vaginal candidiasis occur annually.

Key Market Drivers

Rising Prevalence of Vulvovaginal Candidiasis and Recurrent Infections

One of the primary drivers of growth in the global VVC treatment market is the rising prevalence of both acute and recurrent vulvovaginal candidiasis infections. Vulvovaginal candidiasis is caused predominantly by Candida albicans, and affects a large proportion of women worldwide, especially those of reproductive age. According to the Centers for Disease Control and Prevention (CDC), approximately 75% of all women will experience at least one episode of VVC during their lifetime, and nearly 40-45% of these individuals will experience two or more episodes. Around 5-8% of women are affected by recurrent vulvovaginal candidiasis (RVVC), which is defined as four or more symptomatic episodes within a year. Several factors contribute to this high prevalence: increased antibiotic use, hormonal changes (due to pregnancy or contraceptives), diabetes, immunosuppression (including HIV/AIDS), and the growing use of immunosuppressive medications. The World Health Organization (WHO) notes that nearly 37.7 million people globally were living with HIV as of 2023, a key risk factor for fungal infections such as VVC.

The growing global awareness surrounding women's reproductive health, increased healthcare access, and proactive screening campaigns are further driving diagnosis rates, prompting a higher demand for effective antifungal therapies. Moreover, the global emphasis on sexual health and infection control, particularly in developing regions, has led to increased funding and outreach efforts aimed at early detection and treatment of fungal infections. Collectively, these trends underscore a growing need for both over the counter (OTC) and prescription treatments, fueling market expansion.

Key Market Challenges

Antifungal Resistance and Limited Treatment Efficacy

A significant challenge to the VVC treatment market is the increasing resistance to conventional antifungal drugs, particularly azoles. Repeated and often inappropriate use of azole antifungals such as fluconazole has led to decreased efficacy in many patients, especially those with recurrent vulvovaginal candidiasis (RVVC). Drug-resistant Candida species, including Candida glabrata and Candida auris, are becoming more prevalent and are often harder to treat. The World Health Organization (WHO), in its 2023 publication on fungal priority pathogens, classified Candida auris as a critical priority pathogen due to its high resistance profile, global spread, and association with severe healthcare outbreaks. The WHO has also recognized the urgent need for new antifungal drug development to address growing treatment gaps and antimicrobial resistance (AMR).

Furthermore, research by the Centers for Disease Control and Prevention (CDC) reveals that fluconazole resistance among Candida strains has increased steadily in recent years, complicating treatment decisions for physicians and leading to higher rates of treatment failure. This resistance is compounded by patient non-compliance, self-medication, and lack of definitive diagnostics, especially in low-resource settings. Addressing antifungal resistance requires substantial investment in surveillance, diagnostics, and antimicrobial stewardship programs. However, in many countries, such efforts remain underfunded or fragmented, hindering the timely management of resistant infections and posing a long-term threat to treatment efficacy and patient outcomes.

Key Market Trends

Shift Toward Novel and Non-Azole Antifungal Therapies

A significant trend in the VVC treatment market is the development and growing preference for non-azole antifungal therapies, particularly in cases of recurrent or drug-resistant infections. Traditional azole-based medications (like fluconazole, clotrimazole, and miconazole) have long been the mainstay for treating VVC. However, emerging drug resistance and the limited efficacy of azoles in recurrent infections have necessitated the development of novel antifungal agents. The shift is supported by increased research and regulatory momentum. For instance, the U.S. FDA approved ibrexafungerp, a novel triterpenoid antifungal agent, for the treatment of VVC in 2021. This new class of antifungals works differently from azoles, targeting the fungal cell wall rather than its membrane, offering a promising alternative for patients with azole-resistant candidiasis or intolerance to existing medications.

Government research institutions and funding agencies are also prioritizing antimicrobial resistance (AMR) and fungal infections. The CDC's Antibiotic Resistance Threats Report (2023) includes Candida species as serious threats, especially Candida auris, which is resistant to multiple antifungal drugs. As part of its response, the U.S. government is supporting antifungal drug development under initiatives such as the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB). This trend is likely to grow stronger as more patients and physicians seek effective treatment options for recurrent infections. Moreover, the pharmaceutical industry is investing in oral and topical agents that offer better bioavailability, fewer side effects, and resistance management-driving innovation in the market landscape.

Key Market Players

• Astellas Pharma Inc.
• Mycovia Pharmaceuticals, Inc.
• Basilea Pharmaceutica Ltd.
• Scynexis, Inc.
• Grupo Ferrer Internacional, S.A.
• Pfizer, Inc.
• Pacgen Life Science Corporation
• NovaDigm Therapeutics, Inc.
• Cidara Therapeutics, Inc.
• Amplyx Pharmaceuticals Inc.

Report Scope:

In this report, the Global Vulvovaginal Candidiasis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Vulvovaginal Candidiasis Treatment Market, By Drug Class:

• Clotrimazole
• Nystatin
• Fluconazole
• Ketoconazole
• Terbinafine
• Terconazole
• Others

Vulvovaginal Candidiasis Treatment Market, By Route of Administration:

• Oral
• Intravenous
• Topical

Vulvovaginal Candidiasis Treatment Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Vulvovaginal Candidiasis Treatment Market, By Region:

• North America
  • United States
  • Mexico
  • Canada
• Europe
  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain
• Asia-Pacific
  • China
  • India
  • South Korea
  • Japan
  • Australia
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Vulvovaginal Candidiasis Treatment Market.

Available Customizations:

Global Vulvovaginal Candidiasis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Clinical Trial Analysis

• 5.1. Ongoing Clinical Trials
• 5.2. Completed Clinical Trials
• 5.3. Terminated Clinical Trials
• 5.4. Breakdown of Pipeline, By Development Phase
• 5.5. Breakdown of Pipeline, By Status
• 5.6. Breakdown of Pipeline, By Study Type
• 5.7. Breakdown of Pipeline, By Region
• 5.8. Clinical Trials Heat Map

6. Global Vulvovaginal Candidiasis Treatment Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others)
  • 6.2.2. By Route of Administration (Oral, Intravenous, Topical)
  • 6.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
  • 6.2.4. By Region
  • 6.2.5. By Company (2024)
• 6.3. Market Map
  • 6.3.1. By Drug Class
  • 6.3.2. By Route of Administration
  • 6.3.3. By Distribution Channel
  • 6.3.4. By Region

7. North America Vulvovaginal Candidiasis Treatment Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Route of Administration
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Vulvovaginal Candidiasis Treatment Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Route of Administration
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Canada Vulvovaginal Candidiasis Treatment Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Route of Administration
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Mexico Vulvovaginal Candidiasis Treatment Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Route of Administration
      • 7.3.3.2.3. By Distribution Channel

8. Europe Vulvovaginal Candidiasis Treatment Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Route of Administration
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Europe: Country Analysis
  • 8.3.1. France Vulvovaginal Candidiasis Treatment Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Route of Administration
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Germany Vulvovaginal Candidiasis Treatment Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Route of Administration
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. United Kingdom Vulvovaginal Candidiasis Treatment Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Route of Administration
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. Italy Vulvovaginal Candidiasis Treatment Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Class
      • 8.3.4.2.2. By Route of Administration
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Spain Vulvovaginal Candidiasis Treatment Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Class
      • 8.3.5.2.2. By Route of Administration
      • 8.3.5.2.3. By Distribution Channel

9. Asia-Pacific Vulvovaginal Candidiasis Treatment Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Route of Administration
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. Asia-Pacific: Country Analysis
  • 9.3.1. China Vulvovaginal Candidiasis Treatment Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Route of Administration
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. India Vulvovaginal Candidiasis Treatment Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Route of Administration
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Japan Vulvovaginal Candidiasis Treatment Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Route of Administration
      • 9.3.3.2.3. By Distribution Channel
  • 9.3.4. South Korea Vulvovaginal Candidiasis Treatment Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Drug Class
      • 9.3.4.2.2. By Route of Administration
      • 9.3.4.2.3. By Distribution Channel
  • 9.3.5. Australia Vulvovaginal Candidiasis Treatment Market Outlook
    • 9.3.5.1. Market Size & Forecast
      • 9.3.5.1.1. By Value
    • 9.3.5.2. Market Share & Forecast
      • 9.3.5.2.1. By Drug Class
      • 9.3.5.2.2. By Route of Administration
      • 9.3.5.2.3. By Distribution Channel

10. South America Vulvovaginal Candidiasis Treatment Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Class
  • 10.2.2. By Route of Administration
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Vulvovaginal Candidiasis Treatment Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Class
      • 10.3.1.2.2. By Route of Administration
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Argentina Vulvovaginal Candidiasis Treatment Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Class
      • 10.3.2.2.2. By Route of Administration
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. Colombia Vulvovaginal Candidiasis Treatment Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Class
      • 10.3.3.2.2. By Route of Administration
      • 10.3.3.2.3. By Distribution Channel

11. Middle East and Africa Vulvovaginal Candidiasis Treatment Market Outlook

• 11.1. Market Size & Forecast
  • 11.1.1. By Value
• 11.2. Market Share & Forecast
  • 11.2.1. By Drug Class
  • 11.2.2. By Route of Administration
  • 11.2.3. By Distribution Channel
  • 11.2.4. By Country
• 11.3. MEA: Country Analysis
  • 11.3.1. South Africa Vulvovaginal Candidiasis Treatment Market Outlook
    • 11.3.1.1. Market Size & Forecast
      • 11.3.1.1.1. By Value
    • 11.3.1.2. Market Share & Forecast
      • 11.3.1.2.1. By Drug Class
      • 11.3.1.2.2. By Route of Administration
      • 11.3.1.2.3. By Distribution Channel
  • 11.3.2. Saudi Arabia Vulvovaginal Candidiasis Treatment Market Outlook
    • 11.3.2.1. Market Size & Forecast
      • 11.3.2.1.1. By Value
    • 11.3.2.2. Market Share & Forecast
      • 11.3.2.2.1. By Drug Class
      • 11.3.2.2.2. By Route of Administration
      • 11.3.2.2.3. By Distribution Channel
  • 11.3.3. UAE Vulvovaginal Candidiasis Treatment Market Outlook
    • 11.3.3.1. Market Size & Forecast
      • 11.3.3.1.1. By Value
    • 11.3.3.2. Market Share & Forecast
      • 11.3.3.2.1. By Drug Class
      • 11.3.3.2.2. By Route of Administration
      • 11.3.3.2.3. By Distribution Channel

12. Market Dynamics

• 12.1. Drivers
• 12.2. Challenges

13. Market Trends & Developments

• 13.1. Recent Developments
• 13.2. Mergers & Acquisitions
• 13.3. Product Launches

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products/Services

15. SWOT Analysis: Global Vulvovaginal Candidiasis Treatment Market

16. Competitive Landscape

• 16.1. Astellas Pharma Inc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Mycovia Pharmaceuticals, Inc.
• 16.3. Basilea Pharmaceutica Ltd.
• 16.4. Scynexis, Inc.
• 16.5. Grupo Ferrer Internacional, S.A.
• 16.6. Pfizer, Inc.
• 16.7. Pacgen Life Science Corporation
• 16.8. NovaDigm Therapeutics, Inc.
• 16.9. Cidara Therapeutics, Inc.
• 16.10. Amplyx Pharmaceuticals Inc.

17. Strategic Recommendations

18. About Us & Disclaimer